Mount Yale Investment Advisors LLC Sells 3,197 Shares of AstraZeneca PLC (NASDAQ:AZN)

Mount Yale Investment Advisors LLC lowered its stake in AstraZeneca PLC (NASDAQ:AZN) by 6.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,815 shares of the company’s stock after selling 3,197 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in AstraZeneca were worth $3,725,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. McClarren Financial Advisors Inc. raised its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. acquired a new position in AstraZeneca during the 2nd quarter worth approximately $26,000. Pathway Financial Advisers LLC bought a new position in AstraZeneca in the first quarter worth approximately $29,000. RFP Financial Group LLC grew its stake in AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after acquiring an additional 178 shares during the period. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on AZN shares. TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

AZN opened at $75.90 on Friday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a 50-day moving average of $80.77 and a 200 day moving average of $78.41. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market cap of $235.33 billion, a P/E ratio of 36.67, a PEG ratio of 1.43 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the firm earned $1.08 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. On average, research analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.